NCT03363464View on ClinicalTrials.gov

Comparative Effectiveness of Empagliflozin in the US

Active, not recruitingOBSERVATIONAL
Enrollment

230,000

Participants

Timeline

Start Date

October 16, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Empagliflozin

Empagliflozin

DRUG

DPP-4 inhibitor

dipeptidyl peptidase-4 inhibitor

DRUG

GLP-1 receptor agonist

Glucagon-like peptide-1 receptor agonist

Trial Locations (1)

02120

Bringham Women Hospital, Boston

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY